Hologic, Inc. (NASDAQ:HOLX) Receives $89.91 Consensus PT from Analysts

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $89.91.

Several research analysts have recently weighed in on HOLX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Stephens restated an "overweight" rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. UBS Group increased their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Citigroup cut shares of Hologic from a "buy" rating to a "neutral" rating and cut their target price for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Royal Bank of Canada raised their price target on shares of Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a research note on Tuesday, November 5th.

Hologic Stock Down 0.9 %

HOLX stock opened at $79.00 on Wednesday. Hologic has a one year low of $67.59 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The firm's fifty day moving average is $80.38 and its 200 day moving average is $78.38. The firm has a market cap of $18.35 billion, a PE ratio of 23.72, a P/E/G ratio of 2.51 and a beta of 0.98.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts' consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company's quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm earned $0.89 EPS. On average, research analysts forecast that Hologic will post 4.27 EPS for the current year.

Institutional Investors Weigh In On Hologic

A number of large investors have recently made changes to their positions in the stock. FMR LLC boosted its stake in Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after buying an additional 2,174,093 shares during the last quarter. Swedbank AB acquired a new position in shares of Hologic during the 1st quarter valued at about $120,827,000. Black Creek Investment Management Inc. grew its holdings in shares of Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after purchasing an additional 885,524 shares during the period. Mackenzie Financial Corp increased its position in Hologic by 1,023.3% during the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider's stock worth $66,506,000 after purchasing an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Hologic during the second quarter worth about $39,427,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.